Electronic cigarette oil brand Bantam announced today that its pre-market tobacco product application (PMTA) for non-tobacco nicotine electronic cigarette oil has been accepted by the US Food and Drug Administration (FDA). The brand's application now enters the next stage of the PMTA process - preliminary scientific review, to confirm that the application contains all necessary items and allow for substantive review by the FDA.
On May 13, 2022, Bantam Company submitted an application to the FDA for its non-tobacco nicotine e-cigarette oil and is seeking marketing authorization from the agency.
We have received this acceptance letter, which reflects Bantam's effort to provide high-quality, science-based electronic liquids for adult consumers while also adhering to our responsibility to restrict youth access and use of these products," said Anthony Dillon, Bantam spokesperson. "Bantam continues to support the need for scientific regulation of the electronic liquid industry and is proud of our various PMTA progress. We remain confident in the quality, consistency, and scientific backing of our products.
Prior to submitting an application focused on non-tobacco nicotine, Bantam submitted a PMTA for its tobacco-derived e-liquid to the FDA in September 2020. The application entered scientific review in August 2021 and is still under FDA review.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
